Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
bosutinib
.
Show all posts
Showing posts with label
bosutinib
.
Show all posts
Monday, April 11, 2016
Bosutinib shows 'low' vascular, cardiac event risk profile
›
In continuation of my update on Bosutinib Third-generation tyrosine kinase inhibitor (TKI) study findings suggest that bosutinib i...
Friday, January 15, 2016
Second-line bosutinib offers ‘durable’ response for chronic phase CML patients
›
In continuation of my update on bosutinib Four-year results for an ongoing study of second-line bosutinib indicate that the tyr...
Monday, June 8, 2015
Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance
›
In continuation of my update on bosutinib A Spanish study suggests that bosutinib can help improve or maintain response in pati...
›
Home
View web version
